medigraphic.com
ISSN 1527-3172 (Electronic)

2021, Number 3-4

<< Back Next >>

MEDICC Review 2021; 23 (3-4)

Hypoxemia and Cytokine Storm in COVID-19: Clinical Implications

Machado-Curbelo C, González-Quevedo A

Language: English
References: 44
Page: 54-59
PDF size: 236.66 Kb.


ABSTRACT

One of the most dreadful complications that can occur during the course of COVID-19 is the cytokine storm—also known as cytokine release syndrome—a form of systemic inflammatory response syndrome triggered by SARS-CoV-2 infection.
The cytokine storm is an activation cascade of auto-amplifying cytokines, which leads to excessive activation of immune cells and generation of pro-inflammatory cytokines. It occurs when large numbers of white blood cells are activated and release inflammatory cytokines, in turn activating even more white blood cells, finally resulting in an exaggerated pro-inflammatory–mediated response and ineffective anti-inflammatory control, leading to tissue damage, multiorgan failure, acute respiratory distress syndrome and death. Although cytokine storm pathogenesis is multifactorial, we hypothesize there is a close association between hypoxemia and cytokine storms in COVID-19, although it is difficult to establish the direction of this relationship. Most probably they coexist and, given enough time, one triggers the other in a chain reaction. Careful analysis of the day-to-day clinical evolution of COVID-19 indicates that there are short and slight periods of hypoxemia (confirmed by pulse oximetry and arterial gasometry), even on the day of the onset of persistent cough and/or shortness of breath. We propose the use of continuous positive airway pressure in early stages of COVID-19, at the onset of respiratory symptoms. This non-invasive ventilation method may be useful in individualized treatments to prevent early hypoxemia in COVID-19 patients and thus avoid triggering a cytokine storm. We believe such an approach is relevant everywhere, and in Cuba in particular, since the country has initiated national production of mechanical ventilation systems, including non-invasive ventilators. Moreover, as Cuba’s COVID-19 protocols ensure early patient admission to isolation centers or hospitals, clinicians can prescribe the early use of continuous positive airway pressure as soon as respiratory symptoms begin, averting early hypoxemia and its triggering effect on cytokine storm development, and consequently, avoiding acute respiratory distress syndrome, multi-organ failure, and death.


REFERENCES

  1. Zhang DM, Chen SL. Cytokine storms causedby novel coronavirus 2019 and treatment for cardiacinjury. Eur Rev Med Pharmacol Sci. 2020Dec;24(23):12527–35.

  2. Mitchell WB. Thromboinfl ammation in COVID-19acute lung injury. Paediatr Respir Rev. 2020Sep;35:20–4. DOI: 10.1016/j.prrv.2020.06.004.Epub 2020 Jun 11.

  3. Lang M, Som A, Mendoza DP, Flores EJ,Reid N, Carey D, et al. Hypoxaemia related toCOVID-19: vascular and perfusion abnormalitieson dual-energy CT. Lancet Infect Dis. 2020Dec;20(12):1365–6. DOI: https://doi.org/10.1016/S1473-3099(20)30367-4

  4. Ministry of Public Health (CU). Protocolo deActuación Nacional para la COVID-19 (Versión1.6) 28 marzo 2021 [Internet]. Havana:Ministry of Public Health (CU); 2021 Mar 28[cited 2021 Apr 21]. Available at: https://fi les.sld.cu/editorhome/2021/2003/2028/ministerio-de-salud-publica-protocolo-de-actuacion-nacional-para-la-covid-2019-version-2021-2026-2028-marzo-2021. Spanish.

  5. Gautret P, Million M, Jarrot PA, Camoin-JauL, Colson P, Fenollar F, et al. Natural historyof COVID-19 and therapeutic options. ExpertRev Clin Immunol. 2020 Dec;16(12):1159–84.

  6. Teo JTR, Abidin NH, Cheah FC. Severe acuterespiratory syndrome-Coronavirus-2 infection:a review of the clinical pathological correlationsof Coronavirus disease-19 in children. Malays JPathol. 2020 Dec;42(3):349–61.

  7. Parasher A. COVID-19: Current understandingof its pathophysiology, clinical presentationand treatment. Postgrad Med J. 2021May;97(1147):312–20. DOI: 10.1136/postgradmedj-2020-138577

  8. Ackermann M, Verleden SE, Kuehnel M, HaverichA, Welte T, Laenger F, et al. Pulmonaryvascular endothelialitis, thrombosis, and angiogenesisin Covid-19. N Engl J Med. 2020 Jul 9;383(2):120–8.

  9. Saeed H, Osama H, Madney YM, Harb HS,Abdelrahman MA, Ehrhardt C, et al. COVID-19;current situation and recommended interventions.Int J Clin Pract [Internet]. 2020 Dec 5[cited 2021 Apr 20]. Available at: https://doi.org/10.1111/ijcp.13886. Epub ahead of print.

  10. Dhont S, Derom E, Van Braeckel E, Depuydt P,Lambrecht BN. The pathophysiology of ‘happy’hypoxemia in COVID-19. Respir Res [Internet].2020 Jul 28 [cited 2021 Apr 21];21(198). Availableat: https://doi.org/10.1186/s12931-020-01462-5

  11. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al.Clinical course and risk factors for mortality ofadult inpatients with COVID-19 in Wuhan, China:a retrospective cohort study. Lancet. 2020 Mar28;395(10229):1054–62.

  12. Kim P, Read S, Fauci A. Therapy for early COVID-19: a critical need. JAMA [Internet]. 2020 Dec1 [cited 2021 Apr 22];324(21):2149–50. Availableat: https://doi.org/10.1001/jama.2020.22813

  13. Jose RJ, Manuel A. COVID-19 cytokine storm:the interplay between infl ammation and coagulation.Lancet Respir Med. 2020 Jun;8(6):e46–e47.

  14. Tang L, Yin Z, Hu Y, Mei H. Controlling cytokinestorm is vital in COVID-19. Front Immunol [Internet].2020 Nov 30 [cited 2021 Apr 20];11:570993.Available at: https://www.frontiersin.org/articles/10.3389/fi mmu.2020.570993/full

  15. Jahani M, Dokaneheifard S, Mansouri K.Hypoxia: A key feature of COVID-19 launchingactivation of HIF-1 and cytokine storm. JInfl amm [Internet]. 2020 Oct 29 [cited 2021 Apr21];17(33). Available at: https://doi.org/10.1186/s12950-020-00263-3

  16. Signori D, Bellani G, Calcinati S, Grassi A,Patroniti N, Foti G. Effect of face mask designand bias fl ow on rebreathing during noninvasiveventilation. Respir Care. 2019 Jul;64(7):793–800.

  17. Jaber S, Bellani G, Blanch L, Demoule A, EstebanA, Gattinoni L, et al. The intensive care medicineresearch agenda for airways, invasive andnoninvasive mechanical ventilation. IntensiveCare Med. 2017 Sep;43(9):1352–65.

  18. Bellani G, Grasselli G, Cecconi M, Antolini L,Borelli M, De Giacomi F, et al. Noninvasive ventilatorysupport of COVID-19 patients outside theintensive care units (WARd-COVID). Ann AmThorac Soc [Internet]. 2021 Jan 4 [cited 2021Apr 21];18(6):1020–8. Available at: https://doi.org/10.1513/AnnalsATS.202008-1080OC

  19. De Virgiliis F, Di Giovanni S. Lung innervation inthe eye of a cytokine storm: neuroimmune interactionsand COVID-19. Nat Rev Neurol [Internet]. 2020 Nov [cited 2021 Apr 21];16(11):645–52.Available at: https://doi.org/10.1038/s41582-020-0402-y. Epub 2020 Aug 25.

  20. Serebrovska ZO, C hong EY, Serebrovska TV,Tumanovska LV. Hypoxia, HIF-1α, and COVID-19: from pathogenic factors to potential therapeutictargets. Acta Pharmacol Sin [Internet].2020 [cited 2021 Jul 21];41:1539–46. Availableat: https://doi.org/10.1038/s41401-020-00554-8

  21. Gozzo L, Viale P, Longo L, Vitale DC, DragoF. The potential role of heparin in patients withCOVID-19: beyond the anticoagulant effect. Areview. Front Pharmacol [Internet]. 2020 Aug 21[cited 2021 Apr 23];11:1307. Available at: https://doi.org/10.3389/fphar.2020.01307

  22. Jose RJ, Williams A, Manuel A, Brown JS,Chambers RC. Targeting coagulation activation in severe COVID-19 pneumonia: lessons frombacterial pneumonia and sepsis. Eur RespirRev [Internet]. 2020 Oct 1 [cited 2021 Apr21];29(157):200240. Available at: https://doi.org/10.1183/16000617.0240-2020

  23. Machado C. Early prevention of hypoxemia.2020 Nov 26. Comment on: Kim P, Read SW,Fauci AS. Therapy for early COVID-19: a criticalneed. JAMA [Internet]. 2020 Nov 2020 [cited2021 Apr 21]. Available at: https://doi.org/10.1001/jama.2020.22813

  24. Zhang R, Wu Y, Zhao M, Liu C, Zhou L, Shen S, etal. Role of HIF-1 alpha in the regulation ACE andACE2 expression in hypoxic human pulmonaryartery smooth muscle cells. Am J Physiol LungCell Mol Physiol. 2009 Oct;297(4):L631–40.

  25. Habashi NM, Camporota L, Gatto LA, NiemanG. Functional pathophysiology of SARS-CoV-2induced acute injury and clinical implications. JAppl Physiol. 2021 Mar 1;130(3):877−91. Availableat: https://doi.org/10.1152/japplphysiol.00742.2020

  26. Wang X, Tu Y, Huang B, Li Y, Li Y, Zhang S, et al.Pulmonary vascular endothelial injury and acutepulmonary hypertension caused by COVID-19:the fundamental cause of refractory hypoxemia?Cardiovasc Diagn Ther. 2020 Aug;10(4):892–7.

  27. Zhang J, Tecson KM, McCullough PA. Endothelialdysfunction contributes to COVID-19-associatedvascular infl ammation and coagulopathy. RevCardiovasc Med. 2020 Sep 30;21(3):315–19.

  28. Dandel M. Pathophysiology of COVID-19-associatedacute respiratory distress syndrome. LancetRespir Med [Internet]. 2021 Jan [cited 2021 Apr23];9(1):e4. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837097/

  29. Tan DX, Hardeland R. Targeting host defensesystem and rescuing compromised mitochondriato increase tolerance against pathogens by melatoninmay impact outcome of deadly virus infectionpertinent to COVID-19. Molecules [Internet].2020 Sep 25 [cited 2021 Apr 21];25(19):4410.Available at: https://doi.org/10.3390/molecules25194410

  30. Cellina M, Gibelli D, Valenti Pittino C, Toluian T,Marino P, Oliva G. Risk factors of fatal outcomein patients with COVID-19 pneumonia. DisasterMed Public Health Prep. 2020 Sep 10;1–8. DOI:10.1017/dmp.2020.346

  31. Alraddadi BM, Qushmaq I, Al-Hameed FM, MandourahY, Almekhlafi GA, Jose J, et al. Noninvasiveventilation in critically ill patients with theMiddle East respiratory syndrome. Infl uenzaOther Respir Viruses. 2019 Jul;13(4):382–90.

  32. Matthay MA, Thompson BT, Ware LB. The Berlindefi nition of acute respiratory distress syndrome:should patients receiving high-fl ow nasal oxygenbe included? Lancet Respir Med. 2021 Apr 26.DOI: 10.1016/S2213-2600(21)00105-3

  33. COVID-19 rapid guideline: Community-basedcare of patients with chronic obstructive pulmonarydisease (COPD) [Internet]. London:National Institute for Health and Care Excellence(UK); 2020 Apr 9 [cited 2021 Apr 21]. 13 p. Availableat: https://www.ncbi.nlm.nih.gov/books/NBK566605/pdf/Bookshelf_NBK566605.pdf

  34. Whittle JS, Pavlov I, Sacchetti AD, Atwood C,Rosenberg MS. Respiratory support for adultpatients with COVID-19. J Am Coll Emerg PhysiciansOpen. 2020 Apr;1(2):95–101. https://doi.org/10.1002/emp2.12071.

  35. Alqahtani JS, Mendes RG, Aldhahir A, RowleyD, AlAhmari MD, Ntoumenopoulos G, et al.Global current practices of ventilatory supportmanagement in COVID-19 patients: an internationalsurvey. J Multidiscip Healthc. 2020 Nov18;13:1635–48.

  36. Alviset S, Riller Q, Aboab J, Dilworth K, BillyPA, Lombardi Y, et al. Continuous Positive AirwayPressure (CPAP) face-mask ventilation isan easy and cheap option to manage a massiveinfl ux of patients presenting acute respiratoryfailure during the SARS-CoV-2 outbreak: aretrospective cohort study. PLoS One. 2020 Oct14;15(10):e0240645.

  37. Brusasco C, Corradi F, Di Domenico A, RaggiF, Timossi G, Santori G, et al. Continuous positiveairway pressure in Covid-19 patients withmoderate-to-severe respiratory failure. EurRespir J. 2021 Feb 17;57(2):2002524. DOI:10.1183/13993003.02524-2020

  38. Arina P, Baso B, Moro V, Patel H, Ambler G; UCLCritical Care COVID-19 Research Group. Discriminatingbetween CPAP success and failurein COVID-19 patients with severe respiratory failure.Intensive Care Med. 2021 Feb;47(2):237–9.

  39. Perkins GD, Couper K, Connolly B, Baillie JK,Bradley JM, Dark P, et al. RECOVERY- Respiratorysupport: respiratory strategies for patientswith suspected or proven COVID-19 respiratoryfailure; Continuous Positive Airway Pressure,High-fl ow Nasal Oxygen, and standard care:a structured summary of a study protocol for arandomised controlled trial. Trials [Internet]. 2020Jul 29 [cited 2021 Apr 23];21(1):687. Available at:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388424/

  40. Amirfarzan H, Cereda M, Gaulton TG, LeissnerKB, Cortegiani A, Schumann R, et al. Use ofHelmet CPAP in COVID-19 - A practical review.Pulmonology [Internet]. 2021 Feb 1 [cited 2021Apr 21]. Available at: https://doi.org/10.1016/j.pulmoe.2021.01.008

  41. Simonds AK, Hanak A, Chatwin M, Morrell MJ,Hall A, Parker KH, et al. Evaluation of dropletdispersion during non-invasive ventilation,oxygen therapy, nebuliser treatment and chestphysiotherapy in clinical practice: implications formanagement of pandemic infl uenza and otherairborne infections. Health Technol Assess. 2010Oct;14(46):131–72.

  42. Favero R, Volpato A, Francesco M, Fiore AD,Guazzo R, Favero L. Accuracy of 3D digital modelingof dental arches. Dental Press J Orthod.2019 Jan–Feb;24(1):38e31–37e37.

  43. Pons-Òdena M, Valls A, Grifols J, Farré R, CambraLasosa FJ, Rubin BK. COVID-19 and respiratorysupport devices. Paediatr Respir Rev.2020 Sep;35:61–3.

  44. Walker J, Dolly S, Ng L, Prior-Ong M, SabapathyK. The role of CPAP as a potential bridgeto invasive ventilation and as a ceiling-of-carefor patients hospitalized with Covid-19-Anobservational study. PLoS One. 2020 Dec31;15(12):e0244857. DOI: 10.1371/journal.pone.0244857




2020     |     www.medigraphic.com